List of Tables
Table 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010–2011
Table 2: Generic Growth Strategies, Global, Revenues of Major Drugs Due for Patent Expiry ($m), 2013–2020
Table 3: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006–2011
Table 4: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011–2012
Table 5: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007–2012
Table 6: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006–2012
Table 7: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011–2020
Table 8: Generic Growth Strategies, Notable Authorized Generics Entry, The US, 2010–2012
Table 9: Generic Growth Strategies, Generic Products Launched, Teva, The US, 2011
Table 10: Generic Growth Strategies, Top Five Generic Active Ingredients, STADA Group, Revenue ($m), 2011